Companies: 10,795·Total market cap: $144.5T
Spruce Biosciences, Inc.

Spruce Biosciences, Inc.

SPRBNASDAQHealthcare● Active
$49.32
$-1.11(-2.20%)
Market Cap$67668470
P/E Ratio
52W High$838.125
52W Low$7

Spruce Biosciences, Inc. (SPRB) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

sprb · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Spruce Biosciences, Inc. (SPRB) measures how much investors pay for each dollar of the company's trailing earnings. SPRB's current PE ratio of N/A is calculated by dividing its stock price of $49.32 by its TTM earnings per share of -$27.11.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-3.87
Based on 3 analysts
EPS (TTM)
-$27.11
TTM · diluted EPS
PEG Ratio
-0.02
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Spruce Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2018 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Spruce Biosciences, Inc.
Spruce Biosciences, Inc.You
SPRB
$68MN/A-$27.11
Coeptis Therapeutics, Inc.
Coeptis Therapeutics, Inc.
COEP
$58MN/A-$2.81
Cue Biopharma, Inc.
Cue Biopharma, Inc.
CUE
$76MN/A-$8.42
Equillium, Inc.
Equillium, Inc.
EQ
$98MN/A-$0.24
Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc.
HOWL
$19MN/A-$1.32
IO Biotech, Inc.
IO Biotech, Inc.
IOBT
$1MN/A-$1.45
NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc.
NRXP
$75MN/A-$1.34

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-50.83
2024-12-31
FY2024
$-98.87
2023-12-31
FY2023
$-95.72
2022-12-31
FY2022
$-75.49
2021-12-31
FY2021
$-69.63
2020-12-31
FY2020
$-48.84
2019-12-31
FY2019
$-22.87
2018-12-31
FY2018
$-496.01

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Spruce Biosciences, Inc. (SPRB) measures how much investors pay for each dollar of the company's trailing earnings. SPRB's current PE ratio of N/A is calculated by dividing its stock price of $49.32 by its TTM earnings per share of -$27.11.

PE Ratio = Stock Price ÷ EPS (TTM)
= $49.32 ÷ -$27.11 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

SPRB pe ratio · 6 questions

SPRB's current PE ratio is N/A as of 2026-06-09, based on a stock price of $49.32 and TTM EPS of -$27.11. Data sourced from Financial Modeling Prep via SPRB's SEC 10-K and 10-Q filings.

SPRB PE ratioWhat is SPRB PE ratioCurrent PE ratio of SPRBSPRB PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Spruce Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09